Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Jan;59(1):42–46. doi: 10.1038/bjc.1989.9

Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein.

S P Cole 1, H F Downes 1, M L Slovak 1
PMCID: PMC2246955  PMID: 2569325

Abstract

We have examined the ability of eight compounds to enhance adriamycin (ADM) sensitivity of two human tumour cell lines (a small cell lung cancer cell line, NCI-H69, and a fibrosarcoma cell line, HT1080) and their multidrug-resistant variants. The resistant cell lines (H69AR and HT1080/DR4) do not overexpress P-glycoprotein. Verapamil, nicardipine, perhexiline maleate, chloroquine, tamoxifen, clomiphene, prenylamine and trifluoperazine were tested alone and in combination with ADM for their cytotoxic effects. No major differences in sensitivity between the parent and resistant cell lines were noted when these agents were tested alone, except for HT1080/DR4 cells which exhibited a slight collateral sensitivity to nicardipine and H69AR cells which showed cross-resistance to chloroquine and clomiphene. When the chemosensitisers were combined with ADM no enhanced cytotoxicity of either parent cell line was observed. In HT1080/DR4 cells, verapamil showed only a modest dose-dependent chemosensitising effect while the other compounds had no effect. Verapamil and nicardipine enhanced ADM cytotoxicity in H69AR cells slightly but these effects were not dose-dependent. These results demonstrate that the reversal of drug resistance by verapamil and other calcium antagonists in a dose-dependent fashion is not an invariable property of multidrug-resistant tumour cells.

Full text

PDF
42

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck W. T., Cirtain M. C., Danks M. K., Felsted R. L., Safa A. R., Wolverton J. S., Suttle D. P., Trent J. M. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res. 1987 Oct 15;47(20):5455–5460. [PubMed] [Google Scholar]
  2. Bell D. R., Gerlach J. H., Kartner N., Buick R. N., Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol. 1985 Mar;3(3):311–315. doi: 10.1200/JCO.1985.3.3.311. [DOI] [PubMed] [Google Scholar]
  3. Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987 Feb 15;47(4):936–942. [PubMed] [Google Scholar]
  4. Chlebowski R. T., Block J. B., Cundiff D., Dietrich M. F. Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line. Cancer Treat Rep. 1982 Jan;66(1):121–125. [PubMed] [Google Scholar]
  5. Cole S. P. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol. 1986;17(3):259–263. doi: 10.1007/BF00256695. [DOI] [PubMed] [Google Scholar]
  6. Croop J. M., Guild B. C., Gros P., Housman D. E. Genetics of multidrug resistance: relationship of a cloned gene to the complete multidrug resistant phenotype. Cancer Res. 1987 Nov 15;47(22):5982–5988. [PubMed] [Google Scholar]
  7. Ganapathi R., Grabowski D. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res. 1983 Aug;43(8):3696–3699. [PubMed] [Google Scholar]
  8. Ganapathi R., Yen A., Grabowski D., Schmidt H., Turinic R., Valenzuela R. Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells. Br J Cancer. 1986 Apr;53(4):561–566. doi: 10.1038/bjc.1986.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gerlach J. H., Bell D. R., Karakousis C., Slocum H. K., Kartner N., Rustum Y. M., Ling V., Baker R. M. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol. 1987 Sep;5(9):1452–1460. doi: 10.1200/JCO.1987.5.9.1452. [DOI] [PubMed] [Google Scholar]
  10. Gerlach J. H., Kartner N., Bell D. R., Ling V. Multidrug resistance. Cancer Surv. 1986;5(1):25–46. [PubMed] [Google Scholar]
  11. Gros P., Ben Neriah Y. B., Croop J. M., Housman D. E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 1986 Oct 23;323(6090):728–731. doi: 10.1038/323728a0. [DOI] [PubMed] [Google Scholar]
  12. Hamada H., Hagiwara K., Nakajima T., Tsuruo T. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res. 1987 Jun 1;47(11):2860–2865. [PubMed] [Google Scholar]
  13. Harker W. G., Bauer D., Etiz B. B., Newman R. A., Sikic B. I. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res. 1986 May;46(5):2369–2373. [PubMed] [Google Scholar]
  14. Hindenburg A. A., Baker M. A., Gleyzer E., Stewart V. J., Case N., Taub R. N. Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance. Cancer Res. 1987 Mar 1;47(5):1421–1425. [PubMed] [Google Scholar]
  15. Inaba M., Fujikura R., Tsukagoshi S., Sakurai Y. Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukemia with reserpine. Biochem Pharmacol. 1981 Aug 1;30(15):2191–2194. doi: 10.1016/0006-2952(81)90246-x. [DOI] [PubMed] [Google Scholar]
  16. Kaye S., Merry S. Tumour cell resistance to anthracyclines--a review. Cancer Chemother Pharmacol. 1985;14(2):96–103. doi: 10.1007/BF00434344. [DOI] [PubMed] [Google Scholar]
  17. Kessel D. Interactions among membrane transport systems: anthracyclines, calcium antagonists and anti-estrogens. Biochem Pharmacol. 1986 Aug 15;35(16):2825–2826. doi: 10.1016/0006-2952(86)90196-6. [DOI] [PubMed] [Google Scholar]
  18. Kessel D., Wilberding C. Mode of action of calcium antagonists which alter anthracycline resistance. Biochem Pharmacol. 1984 Apr 1;33(7):1157–1160. doi: 10.1016/0006-2952(84)90533-1. [DOI] [PubMed] [Google Scholar]
  19. Ling V., Thompson L. H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol. 1974 Feb;83(1):103–116. doi: 10.1002/jcp.1040830114. [DOI] [PubMed] [Google Scholar]
  20. Ma D. D., Scurr R. D., Davey R. A., Mackertich S. M., Harman D. H., Dowden G., Isbister J. P., Bell D. R. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet. 1987 Jan 17;1(8525):135–137. doi: 10.1016/s0140-6736(87)91969-6. [DOI] [PubMed] [Google Scholar]
  21. Marsh W., Center M. S. Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells. Cancer Res. 1987 Oct 1;47(19):5080–5086. [PubMed] [Google Scholar]
  22. Mirski S. E., Gerlach J. H., Cole S. P. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res. 1987 May 15;47(10):2594–2598. [PubMed] [Google Scholar]
  23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  24. Ozols R. F., Cunnion R. E., Klecker R. W., Jr, Hamilton T. C., Ostchega Y., Parrillo J. E., Young R. C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987 Apr;5(4):641–647. doi: 10.1200/JCO.1987.5.4.641. [DOI] [PubMed] [Google Scholar]
  25. Ramu A., Fuks Z., Gatt S., Glaubiger D. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. Cancer Res. 1984 Jan;44(1):144–148. [PubMed] [Google Scholar]
  26. Ramu A., Glaubiger D., Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res. 1984 Oct;44(10):4392–4395. [PubMed] [Google Scholar]
  27. Ramu A., Spanier R., Rahamimoff H., Fuks Z. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. Br J Cancer. 1984 Oct;50(4):501–507. doi: 10.1038/bjc.1984.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Russell W. C., Newman C., Williamson D. H. A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasmas and viruses. Nature. 1975 Feb 6;253(5491):461–462. doi: 10.1038/253461a0. [DOI] [PubMed] [Google Scholar]
  29. Shiraishi N., Akiyama S., Kobayashi M., Kuwano M. Lysosomotropic agents reverse multiple drug resistance in human cancer cells. Cancer Lett. 1986 Mar;30(3):251–259. doi: 10.1016/0304-3835(86)90049-2. [DOI] [PubMed] [Google Scholar]
  30. Slater L. M., Sweet P., Stupecky M., Wetzel M. W., Gupta S. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer. 1986 Aug;54(2):235–238. doi: 10.1038/bjc.1986.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Slovak M. L., Hoeltge G. A., Dalton W. S., Trent J. M. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 1988 May 15;48(10):2793–2797. [PubMed] [Google Scholar]
  32. Tormey D. C., Falkson G., Crowley J., Falkson H. C., Voelkel J., Davis T. E. Dibromodulcitol and adriamycin +/- tamoxifen in advanced breast cancer. Am J Clin Oncol. 1982 Feb;5(1):33–39. [PubMed] [Google Scholar]
  33. Tsuruo T., Iida H., Kitatani Y., Yokota K., Tsukagoshi S., Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res. 1984 Oct;44(10):4303–4307. [PubMed] [Google Scholar]
  34. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981 May;41(5):1967–1972. [PubMed] [Google Scholar]
  35. Twentyman P. R., Fox N. E., Bleehen N. M. Drug resistance in human lung cancer cell lines: cross-resistance studies and effects of the calcium transport blocker, verapamil. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1355–1358. doi: 10.1016/0360-3016(86)90170-7. [DOI] [PubMed] [Google Scholar]
  36. Yamaguchi T., Nakagawa M., Shiraishi N., Yoshida T., Kiyosue T., Arita M., Akiyama S., Kuwano M. Overcoming drug resistance in cancer cells with synthetic isoprenoids. J Natl Cancer Inst. 1986 May;76(5):947–953. [PubMed] [Google Scholar]
  37. Zamora J. M., Beck W. T. Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells. Biochem Pharmacol. 1986 Dec 1;35(23):4303–4310. doi: 10.1016/0006-2952(86)90710-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES